Test Price
450 AED✅ Home Collection Available
Immunohistochemistry p63 Test (IHC p63) in Dubai
Executive Summary & Core Metrics
Test Overview & Methodology
The Immunohistochemistry p63 test is a cornerstone in tumor classification, specifically for distinguishing prostatic, squamous, and myoepithelial origins in cancer biopsies. p63 immunohistochemistry identifies basal and myoepithelial cell nuclei for classifying prostate, squamous, and breast cancers accurately. It is a critical immunohistochemical marker employed by pathologists to distinguish benign from malignant lesions and to confirm the origin of poorly differentiated tumors, especially in prostate carcinoma versus high-grade prostatic intraepithelial neoplasia, squamous cell carcinoma, and breast myoepithelial lesions.
Methodology: IHC with monoclonal p63 antibody, validated staining protocol on formalin-fixed paraffin-embedded (FFPE) tissue sections. Automated staining platforms are used to ensure reproducibility and precision.
| Feature | Our p63 IHC Test | Closest Alternative (p40/CK5/6) |
|---|---|---|
| Precision | >99% sensitivity for basal/myoepithelial phenotype | High but variable; p40 limited in prostate differentiation |
| Method | IHC with monoclonal p63 antibody, validated staining protocol | IHC using p40 or CK5/6 antibodies |
| Speed | 5–7 days (tissue biopsy up to complex specimens) | Similar turnaround; often 5–7 days |
Physician Insight & Safety Protocols
Advisory: Medication Safety
Do not discontinue prescribed medication without consulting your doctor. The p63 test is performed on archival tissue and does not require any changes to your current medications. However, if you are undergoing a concurrent biopsy, follow your physician's instructions regarding anticoagulant therapy.
Exclusion Criteria & Safety Guidelines
- Exclusion Criteria: Active bleeding disorder or anticoagulant therapy without physician clearance; patients with severe needle phobia requiring special accommodation.
- ER Red Flags: If you experience increasing pain, heavy bleeding, swelling, or signs of infection at the biopsy site after sample collection, seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What is the p63 test used for?
p63 IHC identifies basal and myoepithelial cell nuclei for classifying prostate, squamous, breast cancers accurately. It is a critical immunohistochemical marker employed by pathologists to distinguish benign from malignant lesions and to confirm the origin of poorly differentiated tumors, especially in prostate carcinoma versus high-grade prostatic intraepithelial neoplasia, squamous cell carcinoma, and breast myoepithelial lesions.
2. How should I prepare for the test?
Submit tumor tissue in formalin or paraffin block with full histopathology report for accurate testing. The referring physician must send the specimen in 10% formalin or a formalin-fixed paraffin-embedded block, along with the biopsy site, clinical history, and a copy of the original histopathology report. No special fasting or medication changes are required for the patient before the biopsy itself; follow your doctor's instructions.
3. When will I receive my results?
p63 immunohistochemistry results are ready in 5–7 business days. Turnaround times depend on specimen complexity; standard FFPE blocks are reported within 5 working days, while large or complex resections may require up to 7 days. We provide secure digital reports and post-test clinical guidance to discuss findings with your oncologist.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with the following federal regulations:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All patient data, including test results and clinical information, are protected under this law. We implement strict access controls and encryption.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Our digital health records and telepathology systems adhere to these standards for secure handling of health information.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: All clinical procedures, including tissue handling and diagnostic reporting, comply with medical liability standards to ensure patient safety and consent.
Clinical & Logistical Metadata
| Property | Value |
|---|---|
| Test Name | Immunohistochemistry p63 Test (IHC p63) |
| Price (AED) | 450 AED |
| Turnaround Time | 5–7 business days |
| Sample Type / Matrix | Formalin-fixed paraffin-embedded (FFPE) tissue block or slides |
| Methodology Used | Immunohistochemistry (IHC) with monoclonal p63 antibody |
| ICD-10-CM Code | C61 |
| LOINC Code | 47527-8 |
| DHA Facility License & Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians